Assessment of Tenofovir effects on bone mineral density in chronic Hepatitis B patients non infected with HIV

Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo0 个研究点开始时间: 2017年12月14日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Have a confirmed diagnosis of chronic hepatitis B; age greater than 18 years; being on Tenofovir for at least 12 months for group 1; being in use of Entecavir or Lamivudine for at least 12 months for group 2; have not made prior use of nucleoside / nucleotide analogues for group 3

•Use of calcium and vitamin D supplements in the last month of inclusion in the study, as well as during the course of the study; liver cirrhosis score CHILD B or C; use of medications to treat osteoporosis; participants with previous thyroidectomy history; presence of chronic renal failure; concomitant HIV infection; concomitant hepatitis C virus infection; use of corticosteroids at doses greater than or equal to 1mg / kg body weight for more than 14 days of inclusion in the study, as well as during the course of the study; rheumatologic disease in activity; menopausal women or with secondary amenorrhea; women taking hormone replacement therapy

发起方

Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo